30-day Perimenopause and Menopause Study Results
Perimenopause and Menopause Consumer Study Results
Thirty-five women completed a structured, open-label consumer study with The Shift, tracking their symptoms weekly across 30 days. This is what the data revealed.
- 9 out of 10 participants said they would recommend The Shift to a friend.
- 75% said they would be very disappointed if The Shift were no longer available.
- 86% reported a meaningful reduction in symptoms within 30 days.
- Average overall well-being rose from 5.6 to 7.2 on a 10-point scale — a 1.6-point gain. 91% improved or maintained. Scores were still rising at Day 30 with no sign of plateau.
- Among women who entered the study with moderate or severe symptoms: 94% showed improvement in brain fog, 93% in irritability, 85% in anxiety, 83% in sleep wakings, and 80% in fatigue by Day 30.
Who participated
Thirty-five women completed the Founder’s Circle between March and April 2026. The group ranged in age from 37 to 67, with a mean age of 46. Roughly half had no hormonal medications. About 21% were on HRT. About 30% were on hormonal birth control. All completed a baseline symptom survey, three weekly check-ins, and a final Day 30 assessment. Product was provided at no cost in exchange for structured, weekly feedback.
Participants followed the Reset protocol: an average of 8 capsules per day, split between morning and evening, with the option to adjust based on sensitivity.
What they were experiencing
The symptom picture was primarily nervous-system in origin. Brain fog, a persistent wired-but-tired state, irritability, and fatigue were all at a level where they were noticeably disrupting daily life. Sleep disruption and anxiety followed closely. Nearly half the group rated brain fog, irritability, and wired-but-tired at severe or extreme levels.
These are the symptoms that most commonly go unnamed in midlife: not dramatic enough for a prescription, disruptive enough to erode quality of life. Many in this group had seen multiple doctors. Some had been told their symptoms were stress or aging. Others had tried HRT and found it helped some things but not these. They were looking for something different.
Well-being over 30 days
Overall well-being was self-rated on a 1 to 10 scale at the start and end of the study. The group entered below a 6, a position where difficult days outnumber good ones. They finished approaching 7.5.
Around 6 is where the ratio flips. Below it, difficult days set the tone. The group crossed that threshold before Week 3 and kept climbing.
These scores were still rising at Day 30 with no sign of plateau. This formula works cumulatively: changes that begin in the first month tend to deepen in months two and three, as the body settles into a new regulatory pattern. These results reflect only the first 30 days of a longer protocol.
How symptoms changed
Improvement rates reflect participants who entered the study with moderate or severe symptoms for each category — the group for whom the formula was most relevant. Severity was rated on a 1-to-5 scale at baseline and again at Day 30. Any decrease in score counts as improvement. Many participants reported early signals within 7 to 14 days, with stronger, more consistent changes by Day 30.
| Symptom | Improved by Day 30 | Avg. score change |
|---|---|---|
| Brain fog | 94% | -1.7 |
| Irritability / short fuse | 93% | -1.5 |
| Anxiety / internal urgency | 85% | -1.4 |
| General fatigue | 80% | -1.1 |
| Sleep wakings | 83% | -1.4 |
Among participants with a baseline severity rating of 3 or higher (moderate to extreme) on a 5-point scale. Brain fog n=31 · Irritability n=27 · Anxiety n=27 · Fatigue n=27 · Sleep wakings n=23. Score change is mean improvement on the 1–5 severity scale.
For most participants, this showed up as clearer thinking, less reactivity, and more stable energy across the day. The symptoms that responded most clearly — brain fog, anxiety, and irritability — are all downstream of nervous system dysregulation. When that layer settles, the cognitive and emotional symptoms tend to follow.
The women who entered with the highest symptom burden improved the most. Every participant who rated brain fog at moderate or severe at baseline showed measurable improvement by Day 30. The formula appears to do more work where there is more to do.
Cycle and PMS symptoms
Among women still experiencing menstrual cycles, 60% reported improvement in PMS mood symptoms and 53% reported improvement in menstrual cramps. These were not part of the original tracking protocol. Participants mentioned cycle changes consistently enough that the questions were added to the final survey — and the signal was strong enough to report. The formula was not designed around cycle support. It appears to be a downstream effect of nervous system regulation.
In their words
What the data tells us
About 21% of participants were already on hormone replacement therapy when the study began. Every one of them improved — with particularly strong gains in irritability and brain fog. HRT typically replaces estrogen. The Shift addresses the nervous system layer that estrogen replacement does not fully resolve. For the women in this group, both approaches worked alongside each other.
The nervous system is the entry point. The symptoms that responded most clearly — sleep, anxiety, irritability, and brain fog — are all downstream of nervous system dysregulation. Women described feeling calmer, not sedated. More even, not flat. The return of capacity to regulate, not the suppression of feeling.
What the adjustment period feels like
Some participants experienced temporary symptoms in the first one to two weeks. For most, this resolved fully by Week 3.
The participants in this study reported the symptoms that most commonly go unaddressed in midlife: brain fog, a wired-but-exhausted state, irritability that arrives faster than it should, and sleep that does not fully restore. Many were not yet in clinical menopause. Several had regular cycles. The common thread was a nervous system under sustained load. If you recognize these symptoms, the protocol used in this study is available now.
